

Author's response to reviews

Title: Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure mouse model
Running title: Mineralocorticoid receptor antagonist, advanced glycation end products, chronic renal failure

Authors:

Chun-Cheng Wang (schwinger1031@gmail.com)

An-Sheng Lee (anshenglee@mmc.edu.tw)

Shu-Hui Liu (sa0983655492@gmail.com)

Kuan-Cheng Chang (kuancheng.chang@gmail.com)

Ming-Yi Shen (shenmy1124@gmail.com)

Chiz-Tzung Chang (ma273737@gmail.com)

Version: 2 Date: 30 Jul 2019

Author's response to reviews:

Reviewer reports:

Sirirat Anutrakulchai, M.D.,PhD (Reviewer 2): Dear the authors

I have suggested some minor corrections. For more properly, please correct as these suggestions.

1. "Differences between before and after treatments in the same group were determined with the paired student's t test."

Answer: Thanks for your comment!! We have modified our description of study method accordingly, please see main manuscript 2nd revised version P. 14, Line 14-15.

2. "To evaluate whether spironolactone has an inhibitory effect on the AGEs/RAGE axis, we pre-treated the AGEs-stimulated HAECs with spironolactone at different concentrations (0.1, 1, and 10 μ M) and the results are presented in Figure 5."

Answer: Thanks for your comment!! We have modified our description of study result accordingly, please see main manuscript 2nd revised version P. 18, Line 7-10.

Aihua Zhang, Ph.D., M.D. (Reviewer 3): My concerns have been addressed. I have no more comments.

Answer: Thanks for the comment!